Blank Rome represented Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) as outside corporate counsel in a private placement providing up to $24 million in gross proceeds, consisting of $5 million in upfront funding and up to an additional $19 million upon the exercise of accompanying milestone-based warrants. The private placement was priced at-the-market under Nasdaq rules. The transaction closed on April 7, 2026.
The sole investors in the private placement are Perceptive Advisors and ADAR1 Capital Management. Kiora intends to use the upfront proceeds from the private placement to support general corporate purposes, including business operations, strategic business development activities, and ongoing research and development.
To learn more about the transaction, please read the press release (April 7, 2026): Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
The Blank Rome team was led by Robert A. Petitt with assistance from Brad L. Shiffman and James A. Sanderson.